Treatment Development for Neuropsychiatric Disturbances in Dementia: Past, Present, Future - Grand Rounds
Johns Hopkins Medicine via YouTube
Overview
Syllabus
Intro
Learning objectives
Facing reality: balancing "cure" with "care"
Auguste D: hospitalized for delusions and change in personality, not cognitive impairment
NPS are UNIVERSAL (97%) & fluctuate Cache County Dementia Progression Study
Eco-psychosocial interventions behavioral, environmental, caregiver focused
Medication treatment development for NPS The past: BEFORE 2011
Medication Rxs disappointing when using existing DSM/ICD phenotypes
Antipsychotics: small benefit Antipsychotics carry "BLACK BOX" warning
Challenges of DSM-IV phenotypes
Overlap of symptoms Cache County Dementia Progression Study
Hypotheses based on etiology
The future: 2023 and beyond Novel medications for agitation
Serotonin system loss in AD early but not universal, interacts with ATN
Response limited to a subgroup HETEROGENEITY
Response depends on agitation phenotype Affective vs. Dysexecutive
Breaking down the heterogeneity of NPS The future: 2023 and beyond
Taught by
Johns Hopkins Medicine